Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab

NCT06816927 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

92

Enrollment

OTHER

Sponsor class

Conditions

Newly Diagnosed Glioblastoma

Interventions

DRUG: Nivolumab
DRUG: Relatlimab
DRUG: TMZ
RADIATION: Radiation Therapy

Sponsor

Duke University